Movement Alert｜3SBio Rises 5.64% in Regular Trading, Biotech Sector Rallies on Innovation Drug Policy Tailwinds

Market Focus07-15

On July 15, 3SBio rose 5.64% in regular trading, trading at HK$18.41/share, with turnover of HK$161 million. The stock rebounded sharply after declining 5.49% in the prior session.

The rally was driven by broad-based strength across the biotech and innovative drug sector, supported by continued policy tailwinds and robust licensing deal activity. Industry data shows that domestic innovative drug outbound BD transactions in the first half of the year reached approximately US$99.7 billion in total value, representing 73% of last year's full-year total and double the 2024 figure. Meanwhile, medical insurance policies supporting innovative drugs continue to be implemented, including a pre-filing mechanism announced in May that accelerates the innovative drug reimbursement pathway.

Within the Biotechnology sector where 3SBio belongs, stocks gained broadly. Among peers, SKB Bio up 9.9%, Innovent Bio up 7.0%, Akeso up 6.83%, Remegen up 4.3%, and BeiGene up 2.37%. 3SBio itself has benefited from its PD-1/VEGF bispecific antibody 707 licensed to Pfizer, with the company also conducting share buybacks totaling 8.52 million shares in June and maintaining a dividend of HK$0.25/share payable in August.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163341228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163341228","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Rises 5.64% in Regular Trading, Biotech Sector Rallies on Innovation Drug Policy Tailwinds","media":"Market Focus","content":"<p><p>On July 15, 3SBio rose 5.64% in regular trading, trading at HK$18.41/share, with turnover of HK$161 million. The stock rebounded sharply after declining 5.49% in the prior session.</p><p>The rally was driven by broad-based strength across the biotech and innovative drug sector, supported by continued policy tailwinds and robust licensing deal activity. Industry data shows that domestic innovative drug outbound BD transactions in the first half of the year reached approximately US$99.7 billion in total value, representing 73% of last year's full-year total and double the 2024 figure. Meanwhile, medical insurance policies supporting innovative drugs continue to be implemented, including a pre-filing mechanism announced in May that accelerates the innovative drug reimbursement pathway.</p><p>Within the Biotechnology sector where 3SBio belongs, stocks gained broadly. Among peers, SKB Bio up 9.9%, Innovent Bio up 7.0%, Akeso up 6.83%, Remegen up 4.3%, and BeiGene up 2.37%. 3SBio itself has benefited from its PD-1/VEGF bispecific antibody 707 licensed to Pfizer, with the company also conducting share buybacks totaling 8.52 million shares in June and maintaining a dividend of HK$0.25/share payable in August.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Rises 5.64% in Regular Trading, Biotech Sector Rallies on Innovation Drug Policy Tailwinds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Rises 5.64% in Regular Trading, Biotech Sector Rallies on Innovation Drug Policy Tailwinds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, 3SBio rose 5.64% in regular trading, trading at HK$18.41/share, with turnover of HK$161 million. The stock rebounded sharply after declining 5.49% in the prior session.</p><p>The rally was driven by broad-based strength across the biotech and innovative drug sector, supported by continued policy tailwinds and robust licensing deal activity. Industry data shows that domestic innovative drug outbound BD transactions in the first half of the year reached approximately US$99.7 billion in total value, representing 73% of last year's full-year total and double the 2024 figure. Meanwhile, medical insurance policies supporting innovative drugs continue to be implemented, including a pre-filing mechanism announced in May that accelerates the innovative drug reimbursement pathway.</p><p>Within the Biotechnology sector where 3SBio belongs, stocks gained broadly. Among peers, SKB Bio up 9.9%, Innovent Bio up 7.0%, Akeso up 6.83%, Remegen up 4.3%, and BeiGene up 2.37%. 3SBio itself has benefited from its PD-1/VEGF bispecific antibody 707 licensed to Pfizer, with the company also conducting share buybacks totaling 8.52 million shares in June and maintaining a dividend of HK$0.25/share payable in August.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1163341228","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163341228","pubTimestamp":1784080426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, 3SBio rose 5.64% in regular trading, trading at HK$18.41/share, with turnover of HK$161 million. The stock rebounded sharply after declining 5.49% in the prior session.The rally was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"走势提醒|3SBio常规交易上涨5.64%，生物技术板块受创新药政策推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On July 15, 3SBio rose 5.64% in regular trading, trading at HK$18.41/share, with turnover of HK$161 million. The stock rebounded sharply after declining 5.49% in the prior session.The rally was driven by broad-based strength across the biotech and innovative drug sector, supported by continued policy tailwinds and robust licensing deal activity. Industry data shows that domestic innovative drug outbound BD transactions in the first half of the year reached approximately US$99.7 billion in total value, representing 73% of last year's full-year total and double the 2024 figure. Meanwhile, medical insurance policies supporting innovative drugs continue to be implemented, including a pre-filing mechanism announced in May that accelerates the innovative drug reimbursement pathway.Within the Biotechnology sector where 3SBio belongs, stocks gained broadly. Among peers, SKB Bio up 9.9%, Innovent Bio up 7.0%, Akeso up 6.83%, Remegen up 4.3%, and BeiGene up 2.37%. 3SBio itself has benefited from its PD-1/VEGF bispecific antibody 707 licensed to Pfizer, with the company also conducting share buybacks totaling 8.52 million shares in June and maintaining a dividend of HK$0.25/share payable in August.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163341228","isCrawlerRequest":true}